WHO Drug Information Vol. 14, No. 4, 2000
(2000; 78 pages)

Table of Contents

	General Policy Issues
		Consumer reporting of adverse drug reactions
	Vaccines and Biomedicines
		Quality assurance and safety of biologicals
	General Information
		Thirty-second Expert Committee on Drug Dependence
	Regulatory and Safety Matters
		Etanercept: serious haematological reactions
		Infliximab: safety restrictions
		Phenylpropanolamine withdrawn from drug products
		Labelling revision for phenylpropanolamine
		Phenylpropanolamine advisory to consumers
		Phenylpropanolamine: strengthening of patient information
		Levacetylmethadol and cardiac disorders
		Bovine-derived materials and vaccines: US recommendations
		Products containing human albumin
		Stavudine and didanosine: pregnancy advisory
		Methysergide and cardiac valvulopathy
		Greater control for cisapride
		New combination drug for HIV
		Tacrolimus for atopic dermatitis
		Letrozole approved for advanced breast cancer
		Alosetron withdrawn
		Basiliximab: hypersensitivity reactions
		Budipine: cardiac reactions
		Capecitabine: revised data sheet
		Benzathine penicillin: fatal mega-unit injections
		Disulfiram: hepatic reactions
		Isoniazid and rifampicin: severe skin reactions
		Omeprazole-induced interstitial nephritis
		Ozagrel sodium: kidney function disorder
		Drug information to the public
		Northern hemisphere influenza vaccine composition
	ATC/DDD Classification (final)
	ATC/DDD Classification (temporary)
	Herbal Medicines
		Research and evaluation of traditional and herbal medicines
		Methodologies for research and evaluation
		The safety of herbal medicines
	Publications and Sources of Information
		Bridging the digital divide
		India publishes ethical guidelines for biomedical research

WHO Drug Information Vol. 14, No. 4, 2000